Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsInvestigators review the clinical presentations of cutaneous immune‐related adverse effects associated with checkpoint inhibitor therapy in adult patients with metastatic malignant melanoma.
[British Journal of Dermatology]
6807162 {6807162:7BG42A5L} apa 50 1 157450 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-089e828470e6bc1f347b3881e22c4f78%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%227BG42A5L%22%2C%22library%22%3A%7B%22id%22%3A6807162%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gault%20et%20al.%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGault%2C%20A.%2C%20Anderson%2C%20A.%20E.%2C%20Plummer%2C%20R.%2C%20Stewart%2C%20C.%2C%20Pratt%2C%20A.%20G.%2C%20%26amp%3B%20Rajan%2C%20N.%20%28n.d.%29.%20Cutaneous%20immune-related%20adverse%20events%20in%20patients%20with%20melanoma%20treated%20with%20checkpoint%20inhibitors.%20%3Ci%3EBritish%20Journal%20of%20Dermatology%3C%5C%2Fi%3E%2C%20%3Ci%3En%5C%2Fa%3C%5C%2Fi%3E%28n%5C%2Fa%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2Fhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjd.19750%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2Fhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjd.19750%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6807162%26amp%3Bitem_key%3D7BG42A5L%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cutaneous%20immune-related%20adverse%20events%20in%20patients%20with%20melanoma%20treated%20with%20checkpoint%20inhibitors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Gault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20E.%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Plummer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20G.%22%2C%22lastName%22%3A%22Pratt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Rajan%22%7D%5D%2C%22abstractNote%22%3A%22Checkpoint%20inhibitor%20%28CPI%29%20therapy%20has%20vastly%20improved%20long-term%20outcomes%20in%20metastatic%20malignant%20melanoma%20%28MMM%29.%20Therapy%20takes%20the%20form%20of%20monoclonal%20antibody%20infusions%20that%20target%20immune%20cell%20checkpoint%20proteins%2C%20such%20as%20cytotoxic%20T-lymphocyte-associated%20protein%204%20%28CTLA4%29%20and%20programmed%20death%201%5C%2Fprogrammed%20death%20ligand%201%20%28PD1%5C%2FPDL1%29.%20Cutaneous%20immune-related%20adverse%20effects%20%28IrAEs%29%20are%20frequent%20in%20patients%20with%20MMM%20treated%20with%20CPIs.%20Our%20aim%20was%20to%20review%20the%20clinical%20presentations%20of%20cutaneous%20IrAEs%20associated%20with%20CPI%20therapy%20in%20adult%20patients%20with%20MMM.%20We%20carried%20out%20a%20literature%20review%20of%20clinical%20trials%2C%20case%20series%20and%20case%20reports%20of%20patients%20with%20melanoma%20and%20those%20with%20other%20cancers%20treated%20with%20anti-CTLA4%2C%20anti-PD1%5C%2FPDL1%2C%20or%20a%20combination%20of%20these%20therapies.%20Diverse%20clinical%20presentations%20of%20cutaneous%20IrAEs%20are%20recognized.%20Anti-CTLA4%20therapy%20has%20a%20higher%20associated%20rate%20of%20cutaneous%20IrAEs%20than%20anti-PD1%5C%2FPDL1%20therapies.%20Low-grade%20cutaneous%20IrAEs%20are%20common%20and%20are%20usually%20managed%20supportively%20while%20continuing%20CPI%20therapy.%20Delayed%20presentations%20arising%20after%20established%20use%20of%20CPIs%20can%20make%20therapy-associated%20cutaneous%20IrAEs%20difficult%20to%20distinguish%20from%20coincidental%20dermatological%20disease.%20Vitiligo-like%20depigmentation%20is%20a%20good%20prognostic%20indicator%20of%20outcome%20in%20patients%20with%20melanoma.%20Life-threatening%20adverse%20events%20including%20toxic%20epidermal%20necrolysis%20are%20rare.%20The%20identification%20of%20predictive%20biomarkers%20that%20highlight%20patients%20at%20risk%20of%20life-threatening%20IrAEs%20remains%20an%20unmet%20need.%20The%20involvement%20of%20dermatologists%20in%20the%20multidisciplinary%20assessment%20of%20cutaneous%20IrAEs%20is%20increasingly%20pertinent%20in%20the%20management%20and%20care%20of%20CPI-treated%20patients%20with%20melanoma.%22%2C%22date%22%3A%22%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbjd.19750%22%2C%22ISSN%22%3A%221365-2133%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fbjd.19750%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-01-04T18%3A45%3A38Z%22%7D%7D%5D%7D
Gault, A., Anderson, A. E., Plummer, R., Stewart, C., Pratt, A. G., & Rajan, N. (n.d.). Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. British Journal of Dermatology, n/a(n/a). https://doi.org/https://doi.org/10.1111/bjd.19750 Cite
